Recombinant Immunotoxin Collaborative Group
Recombinant Immunotoxin Collaborative Group
Overview[edit | edit source]
The Recombinant Immunotoxin Collaborative Group is a consortium of researchers and scientists dedicated to the development and study of recombinant immunotoxins. These are engineered proteins that combine the targeting capabilities of antibodies with the cell-killing ability of toxins. The group focuses on advancing the understanding and application of these molecules in the treatment of various cancers and other diseases.
History[edit | edit source]
The group was formed in the early 2000s, bringing together experts from various institutions to collaborate on the challenges and opportunities presented by recombinant immunotoxins. The initial focus was on improving the specificity and efficacy of these agents, as well as reducing their immunogenicity.
Research Areas[edit | edit source]
The Recombinant Immunotoxin Collaborative Group conducts research in several key areas:
Target Identification[edit | edit source]
Identifying suitable antigens on cancer cells that can be targeted by immunotoxins is a primary focus. The group uses advanced genomics and proteomics techniques to discover novel targets.
Protein Engineering[edit | edit source]
The group works on engineering the protein components of immunotoxins to enhance their stability, reduce off-target effects, and improve their therapeutic index.
Clinical Trials[edit | edit source]
Members of the group are involved in designing and conducting clinical trials to evaluate the safety and efficacy of new recombinant immunotoxins in patients.
Immunogenicity Reduction[edit | edit source]
Reducing the immunogenicity of immunotoxins is crucial for their repeated use in patients. The group explores various strategies, including PEGylation and humanization of antibody components.
Collaborations[edit | edit source]
The Recombinant Immunotoxin Collaborative Group collaborates with various academic institutions, biotechnology companies, and government agencies. These collaborations facilitate the sharing of resources, expertise, and data, accelerating the development of new therapies.
Impact[edit | edit source]
The work of the Recombinant Immunotoxin Collaborative Group has led to significant advancements in the field of targeted cancer therapy. Several immunotoxins developed by the group have entered clinical trials, showing promise in treating leukemia, lymphoma, and other malignancies.
Related pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
